Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 radionuclide therapy for SSTR2-expressing tumors with yttrium-90 DOTATOC or lutetium-177 DOTATATE
2006-000897-65Phase 2Completed
- Sponsor
- Santa Maria Nuova
- Start
- Mar 2007
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, open-label trial of yttrium (90Y) edotreotide and lutetium Lu 177 dotatate in apudoma (NET), breast cancer, bronchial carcinoma and 1 more (2 arms), sponsored by Santa Maria Nuova. Primary endpoints: Antitumor effectiveness, Tumor response at 2 months and 2 more. Started Mar 2007; status: completed.
02
Drugs
yttrium (90Y) edotreotidelutetium Lu 177 dotatate
03
Conditions
apudoma (NET)breast cancerbronchial carcinomathyroid cancer
Beyond the preview
Go deeper on 2006-000897-65.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000897-65.